

VITAL THERAPIES INC  
Form 8-K  
March 29, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): March 29, 2017

VITAL THERAPIES, INC.  
(Exact name of registrant as specified in its charter)

Delaware                      001-36201                      56-2358443  
(State or other jurisdiction      (Commission File Number) (IRS Employer Identification No.)  
of incorporation)

15010 Avenue of Science, Suite 200      92128  
San Diego, CA  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code: (858) 673-6840

---

(Former name or former address, if changed since last report)  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On March 29, 2017, Vital Therapies, Inc. issued a press release announcing that, in connection with its previously disclosed underwritten public offering, the underwriters have exercised in full their option to purchase an additional 1,312,500 shares of its common stock at the offering price of \$4.00 per share, less the underwriting discount. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated March 29, 2017

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VITAL THERAPIES, INC.

By: /s/ Michael V. Swanson  
Michael V. Swanson  
Chief Financial Officer  
Date: March 29, 2017

---

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated March 29, 2017